In patients with systemic lupus erythematosus (SLE) who develop hydroxychloroquine-induced retinopathy, the appropriate treatment involves immediate discontinuation of hydroxychloroquine to prevent progression of retinal toxicity while continuing management of lupus with alternative immunosuppressive agents. Hydroxychloroquine should be stopped promptly once retinopathy is diagnosed because retinal damage may progress even after cessation, but continued exposure significantly increases the risk of vision loss 1. Following withdrawal, lupus activity can be controlled using other established immunosuppressants or corticosteroids depending on disease severity and organ involvement. Agents such as azathioprine, methotrexate, mycophenolate mofetil, or biologics (e.g., belimumab) are considered suitable alternatives that do not carry the same retinal toxicity risk 1[Luboń et al. 2025]. Regular ophthalmologic monitoring is essential for early detection of hydroxychloroquine toxicity in at-risk patients, but once toxicity occurs, cessation remains the primary intervention 1[Geamănu Pancă et al. 2014]. Recent clinical literature emphasizes the importance of individualized treatment approaches balancing adequate suppression of lupus disease activity while minimizing ocular and systemic adverse effects Cheng et al. 2024Luboń et al. 2025.